Navigation Links
Antibiotic treats lymphoma of the eye

The common antibiotic doxycycline effectively treats a type of lymphoma associated with chlamydia infection, according to a study in the October 4 issue of the Journal of the National Cancer Institute.

Ocular adnexal lymphoma of the MALT-type (OAL) is a kind of cancer of the eyelids and related tissues. It is not often fatal, but its symptoms can compromise a patient's quality of life. Some research has suggested an association between OAL and infection with the bacteria Chlamydia psittaci.

Andres J. M. Ferreri, M.D., of the San Raffaele H Scientific Institute in Milan, Italy, and colleagues examined whether doxycycline was an effective treatment for OAL. They gave 27 OAL patients a 3-week course of doxycycline therapy, whether they were positive or negative for chlamydia. They looked for tumor progression every 6 months.

The authors found that doxycycline treatment caused lymphoma to regress in both patients who did not test positive for the disease and those who did. They suggest that doxycycline may be a useful therapy even in patients where other treatments have failed, and it is a valid alternative to chemotherapy and radiation without causing the same toxic side-effects. Patients treated with doxycycline had a 66% rate of disease-free survival.

"Our prospective trial revealed that doxycycline is a fast, safe, and active treatment for OAL, both at initial diagnosis and at relapse," the authors write.

In an accompanying editorial, Emanuel Zucca, M.D., and Francesco Bertoni, M.D., of the Oncology Institute of Southern Switzerland, write, "While doxycycline appears to be an easy-to-implement therapeutic approach, we strongly encourage all physicians to enroll patients in clinical prospective trials to help answer these questions."


'"/>

Source:Journal of the National Cancer Institute


Page: 1

Related biology news :

1. Antibiotic Resistant Bacterium Uses Sonar-like Strategy to “See?Enemies or Prey
2. Antibiotic might fight HIV-induced neurological problems
3. New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal
4. To Stop Evolution: New Way Of Fighting Antibiotic Resistance Demonstrated By Scripps Scientists
5. Chemical Engineer Kao Explores Antibiotic Synthesis With DNA Chips
6. Use of Antibiotics for Acne May Increase Risk of Common Illness
7. Large-scale Computer Simulations Reveal New Insights Into Antibiotic Resistance
8. Antibiotic inhibits cancer gene activity
9. Antarctic ice shelf retreats happened before
10. Stem cell therapy successfully treats heart attack in animals
11. Gene therapy advance treats hemophilia in mouse models
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Antibiotic treats lymphoma the eye

(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
(Date:4/8/2015)... CHARLOTTE, N.C. , April 8, 2015 /PRNewswire/ ... technology solutions and services, and Morpho, a leading ... in partnership to produce the market,s most advanced ... Infinisource,s iSolved NXG time clock is setting ... attendance and labor data for the small and ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... A new study provides support for Darwin,s ... between more closely related species than those distantly ... new study contains the strongest direct experimental evidence ... that species extinction occurred more frequently and more ...
... a better state to recall where you put them at some ... A paper describing the work is published June 13 in the ... "It,s been assumed that the process of retrieving a memory is ... UC Davis Center for Neuroscience and Department of Psychology. "But we ...
... intimate and complex relationship between inflammation and cancer; and it ... attract host cells which drive inflammation and help to support ... Press in the June issue of the journal Cancer ... trafficking of immune cells involved in inflammation. The research ...
Cached Biology News:New study supports Darwin's hypothesis on competition between species 2New study supports Darwin's hypothesis on competition between species 3Brain state affects memory recall 2Blocking common gateway to inflammation suppresses cancer 2
(Date:5/1/2015)... May 1, 2015 According ... Market by Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), ... Labs, Research Institutes) - Analysis & Global Forecast ... the global Antibody Production Market for the forecast ... expected to reach $2.572 Billion by 2019 from ...
(Date:4/30/2015)... 2015 Spirax Sarco, the leader in ... to announce that for the first time in the ... of a Queen’s Award for Innovation – the UK’s ... manufacture of a unique flowmeter. , The Spirax Sarco ... traditional steam flow measurement. The device provides reliable, ...
(Date:4/30/2015)... , April 30, 2015   Tamir Biotechnology ... today an update on its Ebola antiviral therapy program. ... leading candidates, TMR004, is currently being evaluated and considered ... the battle against Ebola. During the first quarter of ... Leadership Meeting To Accelerate The Evaluation of Potential Treatments ...
(Date:4/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), an ... has commenced an underwritten public offering of its common ... a 30-day option to purchase up to an additional ... in the public offering. The offering is subject to ... to whether or when the offering may be completed, ...
Breaking Biology Technology:Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... April 1, NovaBay Pharmaceuticals, Inc. (NYSE Amex: ... developing first-in-class anti-infective products for the treatment and ... causing resistance, reported today its financial results for ... 31, 2008. The company also announced clinical ...
... Submits Contract Proposal to Further Develop Environmental Biosensor ... Biomedical, Inc., a leader in human embryonic stem ... submitted a Department of Defense contract proposal to ... cell technology. (Logo: ...
... 1 /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology,International, Inc. (OTC Bulletin ... of nutrients for plants and animals, located in ... named Mr. Sam Yu to be the,Company,s new ... Mr. Yu,replaces Larry Gilmore, who served as the ...
Cached Biology Technology:NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 2NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 3NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 4NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 5NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 6NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 7NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 8NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results 9ArunA Biomedical Submits Contract Proposal to Further Develop Environmental Biosensor for National Security 2Yongye Biotechnology Appoints New Chief Financial Officer 2Yongye Biotechnology Appoints New Chief Financial Officer 3
MAb to Desmoplakin I & II Desmoplakin I & II...
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
... Activation of ICE-family proteases/caspases initiates apoptosis in ... Apoptosis Detection Kit provides a simple and ... by flow cytometry in intact cells. ... two aspartate residues linked to rhodamine 110 ...
... pLivSelect is a direct antibiotic-based selection system ... on colony survival, eliminating the need for ... process provides close to 100% accuracy in ... platform for robot colony picking. This cloning ...
Biology Products: